Efficacy Of Atosiban Research Articles

Study on Safety and Efficacy of Atosiban and Nifedipine in the Management of Threatened Preterm Labour

Study on Safety and Efficacy of Atosiban and Nifedipine in the Management of Threatened Preterm Labour

Atosiban versus ritodrine as tocolytics in external cephalic version

Objective To assess the efficacy of atosiban versus ritodrine as tocolytics in external cephalic version (ECV). Materials and methods A prospective comparative trial was carried out in a tertiary hospital. 430 women with singleton breech pregnancies ≥36 weeks were recruited for ECV, 215 with ritodrine and 215 with atosiban as tocolytic agents. The efficacy, complications and perinatal outcomes were compared between both groups. The associations between variables were analyzed using the chi-square test (χ2) (qualitative), Student’s t test (quantitative, parametric) or Mann-Whitney test (nonparametric). Statistical significance was established as p < .05. Results The overall ECV success rate was 47.9% (206/430), 46.0% in the atosiban group (99/215) and 49.8% in the ritodrine group (107/215). This difference showed no statistical significance (p = .440). A higher rate of uterine contractions after the maneuver was observed in the atosiban group (34.4 versus 22.8%; p = .008), but without clinical relevance. Perinatal outcomes were similar in both groups, with no significant differences. Conclusion Atosiban and ritodrine showed similar efficacy as tocolytic agents in ECV, with no differences in complications and perinatal outcomes between these two agents.

Сравнительный анализ эффективности атозибана как токолитического средства

Сравнительный анализ эффективности атозибана как токолитического средства

Эффективность применения атозибана при угрожающих преждевременных родах

Эффективность применения атозибана при угрожающих преждевременных родах

COMPAREMENT OF LOCALIZA ATOSIBAN AND HEXOPRENALINE IN PREMATURE DELIVERY BEFORE 32 AND AFTER 32 WEEKS OF PREGNANCY

The aim of the study was to compare the efficacy of tocolytic agents - hexoprenaline and atosiban taking into account the gestational age. Patients and methods . The study included 147 pregnant women with threatening preterm labour between 28 to 33 weeks of gestation. Seventy-three pregnant received tocolysis by hexoprenaline (36 of them before 28 weeks of gestation and 37 – 32 weeks and more) and 74 – atosiban (39 of them before 28 weeks of gestation and 35–32 weeks and more). There were no differences in the clinical condition of pregnant women and features of preterm labour among groups before start of the tocolysis. The degree of effectiveness is determined by the duration of the pregnancy prolongation (48 hours, 7 days, more than 14 days). Results . Depending on the gestational age women that received hexoprenaline tocolysis prolonged pregnancy for 48 hours in 80,6% and 81,1%, whereas in the treatment with atosiban in 94,9% and 100%. Full-term gestation births occurred in 24,3% after hexoprenaline tocolysis at 32 weeks and more and in 51,4% with – atosiban (p < 0,05%). On average, atosiban tocolysis allowed to prolong pregnancy by 6–10 days longer than hexoprenaline (p < 0,05). Conclusion : The results of study have shown that atosiban was more effective tocolytic than hexoprenaline in the treatment of threatening preterm labor in both 28-32 and 32 or more weeks of gestation. The efficacy of atosiban slightly increased with gestational age from 28 to 33 weeks.

Therapy side-effects and predictive factors for preterm delivery in patients undergoing tocolysis with atosiban or ritodrine for threatened preterm labour

The objective of this study was to compare the safety and efficacy of atosiban and ritodrine in the treatment of threatened preterm labour (TPL) and to analyse the predictive factors of preterm delivery. We retrospectively sampled data on 380 women hospitalised for TPL (24–35 weeks’ gestation), in our clinic between 2004 and 2007. All were subjected to tocolysis with ritodrine and/or atosiban. Data were analysed using R (version 2.12.1), considering p < 0.05 as significant. We had 69 women treated with atosiban, 242 treated with ritodrine and 69 treated with ritodrine changed for atosiban, if adverse effects occurred. In the multivariate logistic regression, the use of atosiban vs ritodrine does not play any role in delaying delivery after 48 h or 7 days, whereas the cervical change at the digital examination, high contractions pre/post-therapy ratio, pPROM, cervical length and fibronectin result as predictive factors for both delivery before 48 h or 7 days. Maternal adverse drug effects were significantly more frequent in patients treated with ritodrine, and one single case of pulmonary oedema was observed. We found fewer side-effects in the atosiban than in the ritodrine group and no difference in efficacy. Moreover, the most predictive factors for preterm delivery were fibronectin test, pPROM, digital vaginal examination and uterine contraction persistence. We believe that predictive capacity of these tests could give the opportunity for targeting therapy and limiting drug side-effects and cost.

The oxytocin antagonist atosiban versus the β‐agonist terbutaline in the treatment of preterm labor

Objective. To compare the efficacy and safety of atosiban and terbutaline for the inhibition of preterm labor.Methods. Two hundred and forty‐nine women diagnosed with preterm labor at 23–33 weeks of gestation were enrolled of whom 245 women received treatment, 116 with atosiban and 129 with terbutaline. At randomization, women were stratified by gestational age (≤28 weeks and &gt;28 weeks). Atosiban (iv bolus dose of 6.75 mg, then 300 μg/min for 3 h and 100 μg/min thereafter) and terbutaline (5–20 μg/min) were administered by iv infusion for 13–18 h. Re‐treatment with study drug or an alternative tocolytic agent was allowed. Tocolytic effectiveness was assessed in terms of the number of women undelivered after 48 hours and 7 days and efficacy and tolerability in terms of the number of women remaining undelivered and not requiring alternative tocolytic therapy after 48 hours and 7 days of starting therapy. Safety was assessed in terms of maternal side effects and neonatal morbidity.Results. Tocolytic effectiveness at 48 hours was 86.1% vs 85.3%; p=0.783, and after 7 days it was 76.5% vs 67.4%; p=0.067, in the atosiban and terbutaline groups, respectively. Tocolytic efficacy and tolerability after 48 hours was 72.2% vs 68.2%; p=0.51 and after 7 days was 55.6% vs 43.4%; p=0.08 in the atosiban and terbutaline groups, respectively. Overall, there were fewer clinically important adverse events with atosiban than with terbutaline.Conclusions. The efficacy of atosiban in the inhibition of preterm labor was shown to be comparable to terbutaline. Atosiban had a superior safety profile compared with terbutaline in terms of maternal and fetal adverse events, and comparable infant outcomes.

Editor's Choice

Editor's Choice